SESSION TITLE: COPD Treatment Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD) that has anti-inflammatory properties in both airways and lung parenchyma. However, if roflumilast is able to reduce systemic inflammation in COPD patients remains speculative.
METHODS: In a post-marketing surveillance study, 21 men and one woman with severe COPD age 69.4 ± 7.7 years, received 500 mg roflumilast once daily for 12 weeks. Serum samples were collected before and after 12 weeks of treatment. Markers of inflammation were determined in serum samples using commercially available multiplex sandwich ELISA array (SearchLight, Billerica, MA, USA). Spirometry was performed at the start of roflumilast treatment and after 12 weeks.
RESULTS: Roflumilast significantly reduced the serum levels of proinflammatory cytokine interleukin (IL)-8 (16.6 ± 10 pg/ml vs 12.8 ± 9.5 pg/ml, p = 0.02). Levels of soluble IL-2 (5.3 ± 9.5 pg/ml vs 7.5 ± 10.2 pg/ml, p= 0.36), IL-4 (0.07 ±0.1 pg/ml vs 0.06 ± 0.1 pg/ml, p= 0.49)), IL-10 (1.3 ± 1.6 pg/ml vs 1.04 ± 1 pg/ml, p= 0.2) and IL-13 (1.2 ± 2.3pg/ml vs 1 ± 2.3 pg/mg, p= 0.67) were not affected by treatment. FEV1 remained stable during roflumilast treatment (831.14 cc ± 239.6 vs 873.55 cc ± 237.8, p= 0.11).
CONCLUSIONS: PDE4 inhibition by roflumilast treatment for 12 weeks reduced systemic inflammatory activity in patients with COPD.
CLINICAL IMPLICATIONS: Future studies are needed to further determine whether PDE4 inhibition can attenuate weight loss and muscle wasting related to systemic inflammation in COPD patients.
DISCLOSURE: The following authors have nothing to disclose: Eduardo Marquez-martin, Francisco Ortega, Elena Campano, Carmen de la Horra, Jose Varela, Enrique Calderon
No Product/Research Disclosure Information